Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionIFP Advisors, Inc
Latest Disclosed Ownership3,615 shares
Latest Disclosed Value $ 233,637
IFP Advisors, Inc ownership in HALO / Halozyme Therapeutics, Inc.

On April 13, 2026 - IFP Advisors, Inc filed a 13F-HR form disclosing ownership of 3,615 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $233,637 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 3,646 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of -0.85% during the quarter. The current value of the position is $252,399 USD.

IFP Advisors, Inc has a history of taking positions in derivatives of the underlying security (HALO) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

HALO / Halozyme Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-13 2026-03-31 13F HALOZYME THERAPEUTICS cs 40637H109 3,615 -31 -0.85 234 -4.90 0.0048
2026-02-06 2025-12-31 13F HALOZYME THERAPEUTICS cs 40637H109 3,646 -1,560 -29.97 245 -35.70 0.0055
2026-02-06 2025-09-30 13F/A-1 HALOZYME THERAPEUTICS cs 40637H109 5,206 785 17.76 382 64.22 0.0099
2025-12-02 2025-09-30 13F HALOZYME THERAPEUTICS cs 40637H109 5,206 785 382 0.0098
2025-07-24 2025-06-30 13F HALOZYME THERAPEUTICS cs 40637H109 4,421 2,318 110.22 233 73.13 0.0066
2025-05-05 2025-03-31 13F HALOZYME THERAPEUTICS cs 40637H109 2,103 2,018 2,374.12 134 3,250.00 0.0041
2025-02-04 2024-12-31 13F HALOZYME THERAPEUTICS cs 40637H109 85 85 4 0.0001
2025-02-04 2024-09-30 13F HALOZYME THERAPEUTICS cs 40637H109 0 -2,027 -100.00 0 -100.00
2024-07-30 2024-06-30 13F HALOZYME THERAPEUTICS cs 40637H109 2,027 2,000 7,407.41 106 10,500.00 0.0042
2024-07-30 2024-03-31 13F HALOZYME THERAPEUTICS cs 40637H109 27 27 1 0.0000
2023-10-12 2023-09-30 13F HALOZYME THERAPEUTICS cs 40637H109 0 -23 -100.00 0 0.0000
2023-08-14 2023-06-30 13F/A-1 HALOZYME THERAPEUTICS cs 40637H109 23 -502 -95.62 1 -100.00 0.0000
2023-08-04 2023-06-30 13F HALOZYME THERAPEUTICS cs 40637H109 23 -502 0 0.0000
2023-04-18 2023-03-31 13F HALOZYME THERAPEUTICS cs 40637H109 525 21 4.17 10 0.0004
2023-02-07 2022-12-31 13F HALOZYME THERAPEUTICS cs 40637H109 504 -1,213 -70.65 0 -100.00 0.0003
2022-11-08 2022-09-30 13F HALOZYME THERAPEUTICS cs 40637H109 1,717 803 87.86 38 111.11 0.0010
2022-09-06 2022-06-30 13F/A-1 HALOZYME THERAPEUTICS cs 40637H109 914 0 0.00 18 0.00 0.0006
2022-09-06 2022-03-31 13F/A-1 HALOZYME THERAPEUTICS cs 40637H109 914 886 3,164.29 18 1,700.00 0.0006
2022-08-08 2022-03-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 28 0 1 0.0000
2022-01-12 2021-12-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 28 -1,837 -98.50 1 -98.72 0.0000
2021-10-06 2021-09-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 1,865 -57 -2.97 78 -11.36 0.0016
2021-07-13 2021-06-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 1,922 -1,020 -34.67 88 -28.46 0.0018
2021-04-30 2021-03-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 2,942 618 26.59 123 23.00 0.0024
2021-01-25 2020-12-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 2,324 2,324 100 0.0041
2020-10-29 2020-09-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 0 0 0 0.0000
2020-08-05 2020-06-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 0 0 0 0.0000
2020-05-12 2020-03-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 0 0 0 0.0000
2020-01-17 2019-12-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 0 0 0 0.0000
2019-11-07 2019-09-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 0 0 0 0.0000
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 0 -9,225 -100.00 0 -100.00
2019-06-03 2018-12-31 13F/A-10 HALOZYME THERAPEUTICS INC COM Stock 40637H109 9,225 -2,075 -18.36 132 -35.61 0.0080
2019-01-23 2018-12-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 9,225 -2,075 132 0.0080
2019-06-03 2018-09-30 13F/A-9 HALOZYME THERAPEUTICS INC COM Stock 40637H109 11,300 225 2.03 205 9.63 0.0084
2018-10-25 2018-09-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 11,300 225 205 0.0084
2019-06-03 2018-06-30 13F/A-8 HALOZYME THERAPEUTICS INC COM Stock 40637H109 11,075 -2,300 -17.20 187 -31.00 0.0079
2018-08-07 2018-06-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 11,075 -1,000 187
2019-06-03 2018-03-31 13F/A-7 HALOZYME THERAPEUTICS INC COM Stock 40637H109 13,375 0 0.00 271 0.00 0.0123
2018-05-09 2018-03-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 12,075 -1,300 237
2019-06-03 2017-12-31 13F/A-6 HALOZYME THERAPEUTICS INC COM Stock 40637H109 13,375 1,739 14.94 271 34.16 0.0123
2018-01-24 2017-12-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 13,375 1,739 271
2017-10-30 2017-09-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 11,636 -3,050 -20.77 202 7.45 0.0080
2019-06-03 2017-06-30 13F/A-5 HALOZYME THERAPEUTICS INC COM Stock 40637H109 14,686 1,226 9.11 188 8.05 0.0080
2017-07-31 2017-06-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 14,686 1,226 188
2019-06-03 2017-03-31 13F/A-4 HALOZYME THERAPEUTICS INC COM Stock 40637H109 13,460 2,850 26.86 174 65.71 0.0076
2017-04-26 2017-03-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 13,460 2,850 174
2019-06-03 2016-12-31 13F/A-3 HALOZYME THERAPEUTICS INC COM Stock 40637H109 10,610 1,499 16.45 105 -4.55 0.0051
2017-02-14 2016-12-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 10,610 1,499 105
2016-11-04 2016-09-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 9,111 -1,966 -17.75 110 14.58 0.0057
2019-06-03 2016-06-30 13F/A-2 HALOZYME THERAPEUTICS INC COM Stock 40637H109 11,077 -289 -2.54 96 -11.11 0.0054
2016-08-22 2016-06-30 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 11,077 -289 96
2016-05-02 2016-03-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 11,366 8,530 300.78 108 120.41 0.0065
2016-02-11 2015-12-31 13F HALOZYME THERAPEUTICS INC COM Stock 40637H109 2,836 2,836 49 0.0033
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2019-06-03 2018-06-30 13F/A HALOZYME THERAPEUTICS INC COM Stock Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-05-09 2018-03-31 13F HALOZYME THERAPEUTICS INC COM Stock Call 2,000 39 n/a n/a n/a
2019-06-03 2017-06-30 13F/A HALOZYME THERAPEUTICS INC COM Stock Call 0 -100.00 0 -100.00 n/a n/a n/a
2019-06-03 2017-03-31 13F/A HALOZYME THERAPEUTICS INC COM Stock Call 1,000 13 n/a n/a n/a
2017-04-26 2017-03-31 13F HALOZYME THERAPEUTICS INC COM Stock Call 1,000 13 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.